Search - tctmd.com

Displaying 41 - 58 of 58

Sort: Relevancy | Date

News Industry News

Case Report: Use of OrbusNeich’s Genous™ Stent with Bivalirudin for Acute Coronary Syndrome Patients at Risk for Bleeding Due to Hematological Cancer

December 16, 2012

News Industry News

Boston Scientific Demonstrates Ongoing Structural Heart Advances at Transcatheter Cardiovascular Therapeutics 2012 in Miami

October 23, 2012

News Industry News

Landmark IMPROVE HF Trial Shows Evidence-Based Programs Result in Improvements in Heart Failure Patients Regardless of Race, and Improves Survival

August 30, 2012

News Industry News

Boston Scientific WATCHMAN® Left Atrial Appendage Closure Device Receives CE Mark Approval For Expanded Use

August 26, 2012

News Industry News

FDA Advisory Committee Recommends Against Approval of Oral Anticoagulant XARELTO® to Reduce the Risk of Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome

May 23, 2012

News Industry News

Study of First-in-Class WATCHMAN® Device Shows 75 Percent Reduction in Stroke Risk in Patients with Atrial Fibrillation Not Eligible for Oral Anticoagulation Therapy

May 11, 2012

News Industry News

OrbusNeich’s Genous™ Stent Is a Safe and Effective Option in Patients with ST-Segment Elevation Myocardial Infarction (STEMI)

March 06, 2012

News Industry News

Boston Scientific's WATCHMAN® Device Implanted in First Patients in Latin America

November 15, 2011

News Industry News

First Research Results of Angiomax(R) (Bivalirudin) Versus Heparin in Transcatheter Aortic Valve Interventions Reported at TCT

November 07, 2011

News Industry News

Virmani's crystal ball: Transcatheter valves

November 06, 2011

News Industry News

Regado Biosciences, Inc. Presents Positive Efficacy and Safety Substudy Data from the Phase 2b RADAR Trial for the REG1 Anticoagulation System

November 06, 2011

News Industry News

FDA Approves XARELTO® (rivaroxaban) to Reduce the Risk of Stroke and Systemic Embolism in Patients with Nonvalvular Atrial Fibrillation

November 04, 2011

News Industry News

FDA Advisory Committee Recommends Approval of Oral Anticoagulant Rivaroxaban for the Prevention of Stroke and Systemic Embolism in Patients with Non-Valvular Atrial Fibrillation

September 08, 2011

News Industry News

Favorable Clinical Study Results Reported With Dual Anti-Platelet Therapy After LAA Closure With WATCHMAN® Device

May 18, 2011

News Industry News

On-X Heart Valve PROACT Trial Preliminary Report Provides Evidence Toward Maintaining Patients With Less Warfarin

April 05, 2011

News Industry News

Boston Scientific to Acquire Atritech

January 18, 2011

News Industry News

Bayer’s Rivaroxaban Submitted for Marketing Authorisation in Stroke Prevention in Patients with Atrial Fibrillation in the US

January 04, 2011

News Industry News

Bayer’s Rivaroxaban Submitted for EU Marketing Authorisation in Stroke Prevention in Patients with Atrial Fibrillation as well as for the Treatment of Deep Vein Thrombosis

January 04, 2011

Advertisement

Case Report: Use of OrbusNeich’s Genous™ Stent with Bivalirudin for Acute Coronary Syndrome Patients at Risk for Bleeding Due to Hematological Cancer

Boston Scientific Demonstrates Ongoing Structural Heart Advances at Transcatheter Cardiovascular Therapeutics 2012 in Miami

Landmark IMPROVE HF Trial Shows Evidence-Based Programs Result in Improvements in Heart Failure Patients Regardless of Race, and Improves Survival

Boston Scientific WATCHMAN® Left Atrial Appendage Closure Device Receives CE Mark Approval For Expanded Use

FDA Advisory Committee Recommends Against Approval of Oral Anticoagulant XARELTO® to Reduce the Risk of Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome

Study of First-in-Class WATCHMAN® Device Shows 75 Percent Reduction in Stroke Risk in Patients with Atrial Fibrillation Not Eligible for Oral Anticoagulation Therapy

OrbusNeich’s Genous™ Stent Is a Safe and Effective Option in Patients with ST-Segment Elevation Myocardial Infarction (STEMI)

Boston Scientific's WATCHMAN® Device Implanted in First Patients in Latin America

First Research Results of Angiomax(R) (Bivalirudin) Versus Heparin in Transcatheter Aortic Valve Interventions Reported at TCT

Virmani's crystal ball: Transcatheter valves

Regado Biosciences, Inc. Presents Positive Efficacy and Safety Substudy Data from the Phase 2b RADAR Trial for the REG1 Anticoagulation System

FDA Approves XARELTO® (rivaroxaban) to Reduce the Risk of Stroke and Systemic Embolism in Patients with Nonvalvular Atrial Fibrillation

FDA Advisory Committee Recommends Approval of Oral Anticoagulant Rivaroxaban for the Prevention of Stroke and Systemic Embolism in Patients with Non-Valvular Atrial Fibrillation

Favorable Clinical Study Results Reported With Dual Anti-Platelet Therapy After LAA Closure With WATCHMAN® Device

On-X Heart Valve PROACT Trial Preliminary Report Provides Evidence Toward Maintaining Patients With Less Warfarin

Boston Scientific to Acquire Atritech

Bayer’s Rivaroxaban Submitted for Marketing Authorisation in Stroke Prevention in Patients with Atrial Fibrillation in the US

Bayer’s Rivaroxaban Submitted for EU Marketing Authorisation in Stroke Prevention in Patients with Atrial Fibrillation as well as for the Treatment of Deep Vein Thrombosis

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content